Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 129-135

  Tasneen, Rokeya ^a   Williams, Kathy ^a   Amoabeng, Opokua ^a   Minkowski, Austin ^a   Mdluli, Khisimuzi E ^b   Upton, Anna M ^b   Nuermbergera, Eric L ^a,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; NITROIMIDAZOLE DERIVATIVE; PRETOMANID; PYRAZINAMIDE; SUTEZOLID; TBA 354; UNCLASSIFIED DRUG; 2-NITRO-6-(4-(TRIFLUOROMETHOXY)BENZYLOXY)-6,7-DIHYDRO-5H-IMIDAZO(2,1-B)(1,3)OXAZINE; MOXIFLOXACIN; OPC-67683; OXAZINE DERIVATIVE; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE; TBA-354; TUBERCULOSTATIC AGENT;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; TREATMENT DURATION; TREATMENT OUTCOME; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; COMPARATIVE STUDY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZATION;

ANIMALS; ANTITUBERCULAR AGENTS; CLOFAZIMINE; DIARYLQUINOLINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZINES; OXAZOLES; PYRAZINAMIDE; RANDOM ALLOCATION; TUBERCULOSIS;

EID: 84920127117     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03822-14     Document Type: Article

References (33)

1. Andries K, Gevers T, Lounis N. 2010. Bactericidal potencies of new regimens are not predictive of their sterilizing potencies in a murine model of tuberculosis. Antimicrob Agents Chemother 54:4540-4544. http://dx.doi.org/10.1128/AAC.00934-10.
2. Ibrahim M, Truffot-Pernot C, Andries K, Jarlier V, Veziris N. 2009. Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am J Respir Crit Care Med 180:553-557. http: //dx.doi.org/10.1164/rccm.200807-1152OC.
3. Lenaerts AJ, Hoff D, Aly S, Ehlers S, Andries K, Cantarero L, Orme IM, Basaraba RJ. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 51:3338-3345. http://dx.doi.org/10.1128/AAC.00276-07.
4. Veziris N, Ibrahim M, Lounis N, Andries K, Jarlier V. 2011. Sterilizing activity of second-line regimens containing TMC207 in a murine model of tuberculosis. PLoS One 6:e17556. http://dx.doi.org/10.1371/journal.pone .0017556.
5. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, Shimokawa Y, Komatsu M. 2006. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3:e466. http://dx.doi.org/10.1371 /journal.pmed.0030466.
6. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH. 2008. Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 52:1522-1524. http://dx.doi.org/10.1128/AAC.00074-08.
7. Tasneen R, Tyagi S, Williams K, Grosset J, Nuermberger E. 2008. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 52:3664-3668. http://dx.doi.org/10.1128/AAC.00686-08.
8. Williams KN, Brickner SJ, Stover CK, Zhu T, Ogden A, Tasneen R, Tyagi S, Grosset JH, Nuermberger EL. 2009. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 180:371-376. http://dx.doi.org/10.1164/rccm .200904-0611OC.
9. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, de Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, McNeely DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
10. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, Suh GY, Danilovits M, Ogata H, Kurve A, Chang J, Suzuki K, Tupasi T, Koh WJ, Seaworth B, Geiter LJ, Wells CD. 2012. Delamanid for multidrugresistant pulmonary tuberculosis. N Engl J Med 366:2151-2160. http://dx .doi.org/10.1056/NEJMoa1112433.
11. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, Mendel CM, Spigelman MK. 2012. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380:986-993. http://dx.doi.org/10.1016/S0140-6736(12)61080-0.
12. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012. Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 56:3114-3120. http://dx.doi.org/10.1128/AAC.00384-12.
13. Tasneen R, Li SY, Peloquin CA, Taylor D, Williams KN, Andries K, Mdluli KE, Nuermberger EL. 2011. Sterilizing activity of novel TMC207-and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55:5485-5492. http://dx.doi.org/10.1128 /AAC.05293-11.
14. Mphahlele M, Syre H, Valvatne H, Stavrum R, Mannsåker T, Muthivhi T, Weyer K, Fourie PB, Grewal HM. 2008. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 46:3459-3464. http://dx.doi.org/10.1128/JCM .00973-08.
15. Pierre-Audigier C, Surcouf C, Cadet-Daniel V, Namouchi A, Heng S, Murray A, Guillard B, Gicquel B. 2012. Fluoroquinolone and pyrazinamide resistance in multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 16:221-223. http://dx.doi.org/10.5588/ijtld.11.0266.
16. Anderson RF, Shinde SS, Maroz A, Boyd M, Palmer BD, Denny WA. 2008. Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5Himidazo[ 2,1-b][1,3]oxazine, in aqueous solution. Org Biomol Chem 6:1973-1980. http://dx.doi.org/10.1039/b801859f.
17. Kmentova I, Sutherland HS, Palmer BD, Blaser A, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA, Thompson AM. 2010. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). J Med Chem 53: 8421-8439. http://dx.doi.org/10.1021/jm101288t.
18. Palmer BD, Thompson AM, Sutherland HS, Blaser A, Kmentova I, Franzblau SG, Wan B, Wang Y, Ma Z, Denny WA. 2010. Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5Himidazo[ 2,1-b][1,3]oxazine (PA-824). J Med Chem 53:282-294. http://dx .doi.org/10.1021/jm901207n.
19. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344. http://dx.doi.org/10.1371/journal .pmed.0040344.
20. Tyagi S, Nuermberger E, Yoshimatsu T, Williams K, Rosenthal I, Lounis N, Bishai W, Grosset J. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob Agents Chemother 49:2289-2293. http://dx.doi.org/10.1128/AAC.49.6 .2289-2293.2005.
21. Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V. 2006. Combinations of R207910 with drugs used to treat multidrugresistant tuberculosis have the potential to shorten treatment duration. Antimicrob Agents Chemother 50:3543-3547. http://dx.doi.org/10.1128 /AAC.00766-06.
22. Williams KN, Stover CK, Zhu T, Tasneen R, Tyagi S, Grosset JH, Nuermberger E. 2009. Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model. Antimicrob Agents Chemother 53:1314-1319. http://dx.doi.org/10.1128 /AAC.01182-08.
23. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56:4331-4340. http://dx.doi.org/10.1128/AAC.00912-12.
24. Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. 2012. Pharmacokinetics-pharmacodynamics of TMC207 and its N -desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 56:1444-1451. http://dx.doi.org/10 .1128/AAC.00720-11.
25. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-2625. http://dx.doi.org/10.1128/AAC.00451-06.
26. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS One 7:e30479. http://dx.doi.org/10 .1371/journal.pone.0030479.
27. Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. 2010. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 54:3402-3407. http://dx.doi.org/10.1128/AAC .01354-09.
28. Alffenaar JWC, van der Laan T, Simons S, van der Werf TS, van de Kasteele PJ, de Neeling H, van Soolingen D. 2011. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of linezolid, PNU-100480. Antimicrob Agents Chemother 55:1287-1289. http://dx.doi.org/10.1128/AAC.01297-10.
29. Wallis RS, Jakubiec W, Kumar V, Bedarida G, Silvia A, Paige D, Zhu T, Mitton-Fry M, Ladutko L, Campbell S, Miller PF. 2011. Biomarkerassisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 55:567-574. http://dx.doi.org/10.1128/AAC.01179-10.
30. Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 202:745-751. http://dx.doi.org/10.1086/655471.
31. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. 2012. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56:3027-3031. http://dx.doi.org/10 .1128/AAC.06125-11.
32. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 15:949-954. http://dx.doi.org/10 .5588/ijtld.10.0616.
33. Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG. 2015. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59:136-144. http://dx.doi.org/10.1128/AAC PA-824 and TBA-354 in Novel TB Regimens